{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:17:08Z","timestamp":1791998228457,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.annonc.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:29:31Z","timestamp":1781713771000},"page":"1414-1422","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Becotatug vedotin for recurrent\/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial"],"prefix":"10.1016","volume":"37","author":[{"given":"F.","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.Q.","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.H.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.Q.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.L.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.F.","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.Q.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.Y.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.Q.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.J.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.G.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1683-1269","authenticated-orcid":false,"given":"Y.J.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.Z.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.L.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.W.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.W.","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.S.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9771-8534","authenticated-orcid":false,"given":"R.H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2026.06.003_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: a multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2026.06.003_bib2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1038\/s41591-021-01444-0","article-title":"Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial","volume":"27","author":"Mai","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.06.003_bib3","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1001\/jama.2023.22465","article-title":"Immunotherapy for nasopharyngeal carcinoma: the earlier the better","volume":"330","author":"Bossi","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.annonc.2026.06.003_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: a phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003790","article-title":"Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.annonc.2026.06.003_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2024.106723","article-title":"Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): a phase II multicenter study","volume":"151","author":"Chen","year":"2024","journal-title":"Oral Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib7","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41392-024-01865-6","article-title":"Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.annonc.2026.06.003_bib8","article-title":"Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase 2 study","volume":"31","author":"Shi","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.annonc.2026.06.003_bib9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/cac2.12218","article-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","volume":"41","author":"Tang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.annonc.2026.06.003_bib10","series-title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","year":"2024"},{"key":"10.1016\/j.annonc.2026.06.003_bib11","series-title":"Head and Neck Cancers. Version 2.2025","year":"2025"},{"key":"10.1016\/j.annonc.2026.06.003_bib12","article-title":"Prognostic role of EGFR\/p-EGFR in patients with nasopharyngeal carcinoma: a meta-analysis","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110649","article-title":"Anti-EGFR therapies in nasopharyngeal carcinoma","volume":"131","author":"Chen","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.annonc.2026.06.003_bib14","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1001\/jamaoncol.2022.0503","article-title":"Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial","volume":"8","author":"Qiu","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2026.101029","article-title":"Becotatug vedotin, MRG003, in previously treated recurrent or metastatic nasopharyngeal carcinoma: a multicenter, single-arm, phase IIa trial","volume":"7","author":"Han","year":"2026","journal-title":"Med"},{"key":"10.1016\/j.annonc.2026.06.003_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib17","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.2005.02.147","article-title":"Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma","volume":"23","author":"Chan","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib18","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/1078-0432.CCR-17-1667","article-title":"Efficacy, safety, and pharmacokinetics of axitinib in nasopharyngeal carcinoma: a preclinical and phase II correlative study","volume":"24","author":"Hui","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2026.06.003_bib19","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/annonc\/mdq425","article-title":"Docetaxel is effective in heavily pretreated patients with disseminated nasopharyngeal carcinoma","volume":"22","author":"Ngeow","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib20","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib21","doi-asserted-by":"crossref","first-page":"4893","DOI":"10.1038\/s41467-023-40402-x","article-title":"Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent\/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"14","author":"Yuan","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.annonc.2026.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102043","article-title":"Camrelizumab plus famitinib in patients with recurrent or metastatic nasopharyngeal carcinoma treated with PD-1 blockade: data from a multicohort phase 2 study","volume":"61","author":"Ding","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.annonc.2026.06.003_bib23","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","article-title":"Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China","volume":"406","author":"Yang","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.annonc.2026.06.003_bib24","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.annonc.2026.06.003_bib25","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s12094-025-04190-8","article-title":"Pharmacovigilance study and development of a clinical decision flowchart for personalized selection of trastuzumab, T-DXd, and T-DM1 in breast cancer patients","volume":"28","author":"Yang","year":"2026","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.annonc.2026.06.003_bib26","article-title":"Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review","author":"Santos Nussbaum","year":"2026","journal-title":"Cardiooncology"},{"key":"10.1016\/j.annonc.2026.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102772","article-title":"A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: charting the course of future therapies","volume":"128","author":"Jim\u00e9nez-Labaig","year":"2024","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426009361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:01:38Z","timestamp":1790193698000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426009361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0923753426009361"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.06.003","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Becotatug vedotin for recurrent\/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}